Last reviewed · How we verify
NCT06583382
Cementation of Cup and the Risk of Second Revision
trial in Total Hip Arthroplasty (THA) in 60,000 participants. Not yet recruiting.
1 October 2025
Quick facts
| Lead sponsor | Bispebjerg Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 60,000 |
| Start date | 1 October 2024 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 October 2026 |
Conditions studied
- Total Hip Arthroplasty (THA) — all drugs for Total Hip Arthroplasty (THA) →
- Revision Hip Arthroplasty — all drugs for Revision Hip Arthroplasty →
Sponsor
Bispebjerg Hospital
Who can join
18 and older, any sex, with Total Hip Arthroplasty (THA) or Revision Hip Arthroplasty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: The fixation method of the acetabular component during the primary total hip arthroplasty (THA) affects the surgical techniques implemented in the revision surgery and may influence the risk of second revision. Objectives: The objectives of this study are to investigate the risk of second revision of the cup alone or any component after first cup revision following cemented or non-cemented cup in the primary THA. Methods/design: The study is a nationwide register-based cohort study and will follow the reporting of studies Conducted using Observational Routinely collected health Data (RECORD) guidelines. We will compare the risk of undergoing a second revision between cemented and uncemented revised acetabular component by reporting the absolute risk of second revision of 1) the acetabular component and 2) any other component. The cumulative incidence of revision will be estimated using Fine-Gray regression to model the cumulative incidence function, accounting for the competing risk of death. We will apply both a crude and a multivariable adjusted model adjusting for age, sex, Charlson Comorbidity Index (CCI) and the 5-year intervals during which the primary operation was performed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06583382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Total Hip Arthroplasty (THA)
Currently open trials in the same condition.
- NCT07392515 — Cognitive and Physical Recovery After Hip Fracture in Frail Patients Using Digital Rehabilitation Technology · NA · recruiting
- NCT07427758 — Effect of Cognitive Behavioral Therapy on Kinesiophobia and Functional Outcomes After Total Hip Arthroplasty. · NA · recruiting
- NCT06883591 — Triaxial Accelerometry Study · active not recruiting
- NCT07453498 — Evaluating the Efficacy of the Psoas Sheath Block for Post Operative Analgesia Following Hip Arthroplasty · NA · recruiting
- NCT07226700 — Suzetrigine in Total Hip Arthroplasty · Phase 3 · recruiting
Other Bispebjerg Hospital trials
Trials by the same sponsor.
- NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
- NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
- NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
- NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
- NCT07096648 — Alert Burden When Monitoring Patients at Home · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06583382 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06583382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing